cosmegen
Cosmegen (Dactinomycin) is an actinomycin used to treat Choriocarcinoma, Melanoma, Wilms Tumor, Neuroblastoma.
Dactinomycin · by Recordati Rare
Key facts
- Active ingredient
- Dactinomycin
- Drug class
- Actinomycin
- Form
- Injectable
- Strength
- Dactinomycin 0.5MG/VIAL **Federal Register Determination That Product was not Discontinued or Withdrawn for Safety or Effectiveness reasons**
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- May treat
- choriocarcinoma, melanoma, wilms tumor
- Manufacturer
- Recordati Rare
- FDA application
- NDA050682
- Availability
- Discontinued (per FDA)
Drug class
May treat (source: NIH RxClass)
- choriocarcinoma
- melanoma
- wilms tumor
- neuroblastoma
- retinoblastoma
- rhabdomyosarcoma
Dosage forms
Injectable
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Cosmegen treat?
- Cosmegen (Dactinomycin) may be used to treat choriocarcinoma, melanoma, wilms tumor, neuroblastoma, retinoblastoma, rhabdomyosarcoma, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- Is there a coupon or discount for Cosmegen?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Cosmegen. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Cosmegen?
- Cosmegen is marketed by Recordati Rare. You can see Recordati Rare's full profile, rating, and other products on pharmaranks.
- Is Cosmegen a brand-name or generic drug?
- Cosmegen is a brand-name product with the active ingredient Dactinomycin.
- Is Cosmegen available over the counter?
- No. Cosmegen is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Cosmegen come in?
- Cosmegen is currently marketed as injectable, per the FDA's National Drug Code Directory.
- What class of drug is Cosmegen?
- Cosmegen is classified as actinomycin, per the FDA's Established Pharmacologic Class.
- Is Cosmegen FDA-registered?
- Cosmegen is on record with the U.S. FDA under application number NDA050682. You can verify this on its official FDA label.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about DACTINOMYCIN
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 2,249 reports naming DACTINOMYCIN — the active ingredient in Cosmegen, and the FDA flagged 98% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- febrile neutropenia196 reports
- neutropenia128 reports
- vomiting108 reports
- thrombocytopenia104 reports
- pyrexia92 reports
- anaemia87 reports
- venoocclusive liver disease77 reports
- stomatitis76 reports
Read these as a signal, not a rate. A report does not mean DACTINOMYCIN caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 25, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
opdivo
Nivolumab
tecentriq
Atezolizumab
xatmep
Methotrexate Sodium
cotellic
Cobimetinib Fumarate
mekinist
Trametinib Dimethyl Sulfoxide
tafinlar
Dabrafenib Mesylate
Compare Cosmegen head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
cosmegen
New